ArticleInternational journal of chronic obstructive pulmonary disease2025
Validation of an AI-Powered Smart Dry Powder Inhaler (RS01X) for Asthma and COPD in a Clinical Setting.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determination of the optimal resistance in RS01 for robust aerosol performance of inhaled controlled-release budesonide powder for chronic obstructive inflammatory respiratory diseases patients.International journal of pharmaceutics: X · 2026Article
- Artificial Intelligence-Based Optimization of Pulmonary Drug Delivery Performance in Smart Inhaler Drug-Device Combination Systems.Pharmaceutics · 2026Review
- Development of an AI-Empowered Novel Digital Monitoring System for Inhalation Flow Profiles.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The main treatment for patients with chronic obstructive pulmonary disease (COPD) or asthma is inhalation medication. Treatment efficacy is often suboptimal due to poor therapy adherence and errors in inhalation technique. The RS01X Methods: This monocenter cross-sectional study with 97 participants comprises patients with COPD, asthma and healthy participants. Participants performed three inhalations with the smart DPI. The inhalations differed in duration, volume and PIF, and orientation of the inhaler (horizontal (correct) and at a 45-degree angle (incorrect)). A paired sample Results: The correlation between the smart DPI and the IPR shows for all the inhalation parameters an ICC > 0.95 (all p < 0.001). Analyses for healthy subjects, and patients with COPD and asthma show no relevant differences between the groups (all ICC > 0.93, all P < 0.001). Inhalations with the inhaler in an incorrect 45-degree angle show negligible but statistically significant differences on the parameters volume (0.44 milliliters) and PIF (1.5L/min) between IPR and smart DPI (P < 0.05). Discussion: The smart DPI is a valid instrument for measuring inhalation parameters to improve therapy adherence and inhalation techniques in patients with asthma and COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.